New perspectives of valproic acid in clinical practice

@article{Cincarova2013NewPO,
  title={New perspectives of valproic acid in clinical practice},
  author={Lenka Cincarova and Zbyněk Zdr{\'a}hal and Jiř{\'i} Fajkus},
  journal={Expert Opinion on Investigational Drugs},
  year={2013},
  volume={22},
  pages={1535 - 1547}
}
Introduction: Valproic acid (VPA) has been used in clinical practice as an anticonvulsant for more than four decades. Its pharmacokinetics and toxicity are thus well documented. VPA is also a potent class-selective histone deacetylase (HDAC) inhibitor at nontoxic therapeutic concentrations. New areas of application for VPA are currently opening up in clinical practice. Areas covered: The authors discuss VPA and how it may serve as an effective drug for cancer therapy. This is due to its ability… 
Valproic Acid and Breast Cancer: State of the Art in 2021
TLDR
The current state of knowledge of the impact of valproic acid (VPA) on different histological subtypes of BC, used in monotherapy or in combination with other active agents in experimental studies in vitro and in vivo is provided.
Review of Sodium Valproate Clinical and Biochemical Properties
TLDR
The aim of this study was to provide a review of drug management among adult epileptic population and to specify the amount and effects of administrated dose an attentive pharmacotherapy- guideline seems to be useful.
Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning.
TLDR
A population pharmacokinetic model is built that would describe the time course of VPA and its selected metabolites when the drug is ingested in an overdose situation and showed that the β-oxidation process exhibited Michaelis-Menten kinetics becoming saturated during acute intoxication.
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
TLDR
Drug repurposing appears as an attractive strategy for drug development in MPM, since the known pharmacology and safety profile based on previous approvals of repurposed drugs allows for faster time-to-market for patients and lower treatment cost.
RECURRENT GASTRIC POLYPOSIS IN A PATIENT USING ANTIEPILEPTIC DRUGS FOR A LONG TIME.
  • O. Ozturk, S. Koklu, H. Koklu
  • Medicine
    Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
  • 2017
TLDR
A 56-year-old woman was admitted with a history of burning sensation in her stomach for years and has used VPA and carbamazepine for bipolar disorder since 2006, and multiple small polyps were detected in the stomach and removed by endoscopic polypectomy.
Effects of Two-by-Two Combination Therapy with Valproic Acid, Lithium Chloride, and Celecoxib on the Angiogenesis of the Chicken Chorioallantoic Membrane
TLDR
2-by-2 combinations of VPA, CX, and LiCl can be considered an effective antiangiogenesis therapeutic modality and were more effective in decreasing angiogenesis than the use of each drug alone.
Study the effect of a drug depakene (Valproic acid) in the serum levels of immune proteins in albino male rats
This study aimed to investigate the effect of administration of depakene (valproic acid)(VPA) (15 mg/Kg of body weight, orally) on serum protein levels, including immune proteins, because its
Anticonvulsant therapy in brain-tumor related epilepsy
TLDR
At present levetiracetam is the preferred drug in brain tumor-related epilepsy, especially when drug interactions need to be avoided, and the decision to withdraw AEDs must carefully consider the risk of seizure recurrence.
Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells
TLDR
It is concluded that epidrug treatment, in particular with combined 5-aza-dC and VPA treatment, might hold promise for improving and adding to current SSA treatment strategies of patients with pNETs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 124 REFERENCES
Valproate: past, present, and future.
TLDR
The mechanisms of VPA which seem to be of clinical importance include increased GABAergic activity, reduction in excitatory neurotransmission, and modification of monoamines, which are discussed in relation to the various clinical uses of the drug.
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
TLDR
Neurocognitive impairment dominated the toxicity profile, with grade 3 or 4 neurological side effects occurring in 8 out of 26 patients, and dose-limiting toxicity (DLT) was the main DLT of infusional VPA.
Clinical Pharmacokinetics of Valproic Acid — 1988
TLDR
Sodium valproic acid has been widely used in the last decade and is now considered a relatively safe and effective anticonvulsant agent and its use in the treatment of anxiety, alcoholism and mood disorders, although these indications require further clinical studies.
Mechanisms of action of valproate: a commentatory
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
TLDR
It is suggested that a clinically safe dose of VPA can enhance radiation-induced cytotoxicity in human ESCC cells by chromatin decondensation with histone hyperacetylation and downregulation of Rad51.
Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
TLDR
VPA and VPA analogs induce differentiation in hematopoietic cell lines in a p21-dependent manner, and the order of potency for induction of differentiation parallels the potencies for inhibition in vitro, supporting the argument that differentiation caused by VPA is mediated through inhibition of HDACs.
Anti‐tumor mechanisms of valproate: A novel role for an old drug
TLDR
The findings elucidate an important role of VPA for cancer therapy and suggest VPA might also be useful as low toxicity agent given over long time periods for chemoprevention and/or for control of residual minimal disease.
HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo
TLDR
The addition of the HDAC inhibitor valproic acid to adenoviral mediated cancer gene therapy clinical trials to enhance adenOViral mediated gene delivery to the tumor cells is supported.
Teratogenicity of valproate conjugates with anticonvulsant activity in mice
TLDR
VPA-AMA has a comparable teratogenicity as does VPA, and it is proposed that the teratogensicity of VPA- AMA is due to the parent compound.
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial
TLDR
Preliminary results of this phase-II study suggest that the combination of hydralazine and valproate is a promising non-toxic and effective therapy for MDS.
...
1
2
3
4
5
...